Skip to content

Randomized Clinical Trial for the Treatment of Lateral Epicondylitis with Debridement Arthroscopic Versus Cytokine-Rich Autologous Serum. (SARC)

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-515941-40-00
Enrollment
86
Registered
2024-11-20
Start date
Unknown
Completion date
Unknown
Last updated
2024-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epicondylitis

Brief summary

In the case of the group of patients treated with SARC, the treatment consists of 2 infiltrations at an interval of 14 to 21 days. If, due to medical criteria, the researcher decides to perform a single infiltration, will consider that the subject has been withdrawn from treatment. However, it will carry out the same monitoring and control visits as for the rest of the patients.

Detailed description

Unexpected systemic infections or infections in the infiltration zone or fever related to suspected infection., Anaphylactic shock or other serious toxicities related to the treatment. Treatment will be restarted at the discretion of the investigators., Edema in the treated area not associated with infiltration. It will restart the treatment according to the investigators' criteria.

Interventions

Sponsors

Parc Tauli Hospital Universitari
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
In the case of the group of patients treated with SARC, the treatment consists of 2 infiltrations at an interval of 14 to 21 days. If, due to medical criteria, the researcher decides to perform a single infiltration, will consider that the subject has been withdrawn from treatment. However, it will carry out the same monitoring and control visits as for the rest of the patients.

Secondary

MeasureTime frame
Unexpected systemic infections or infections in the infiltration zone or fever related to suspected infection., Anaphylactic shock or other serious toxicities related to the treatment. Treatment will be restarted at the discretion of the investigators., Edema in the treated area not associated with infiltration. It will restart the treatment according to the investigators' criteria.

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026